Predicting beta-interferon failure in relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 13, Issue 3, 2007, Pages 336-342

  O'Rourke, K ^a   Walsh, C ^b   Antonelli, G ^c   Hutchinson, Michael ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Beta interferon; Historical controls; Multiple sclerosis; Progression; Relapse; Treatment failure

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISABILITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; PREDICTION; RECURRENCE RISK; RELAPSE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT;

ADULT; AGE OF ONSET; BIOLOGICAL RESPONSE MODIFIERS; COHORT STUDIES; DISABILITY EVALUATION; DISABLED PERSONS; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RECURRENCE; TIME FACTORS; TREATMENT FAILURE;

EID: 34248180598     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506071309     Document Type: Article

References (26)

1. IFNβ Multiple Sclerosis Study Group, the University of British Columbia MS/MRI analysis group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 1995; 45: 1277-85.
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
3. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
4. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-55.
5. Association of British Neurologists. Guidelines for the use of beta-interferon and glatiramer acetate in multiple sclerosis. Association of British Neurologists, 2001.
6. Waubant E, Vukusic S, Gignoux L, Durand-Dubief F, Achiti I, Blanc S et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-89.
7. Sorensen PS, Ross C, Clemmensen K, Bendtzen K, Frederiksen JL, Jensen K et al. Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
8. Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capabianco M et al. Neutralizing antibodies reduce the efficacy of IFNβ during treatment of multiple sclerosis. Neurology 2004; 62: 2031-37.
9. Poser CM, Paty DW, Scheinberg LC, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
10. O'Rourke KET, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005; 11: 46-50.
11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin F, McFarland H et al. Recommended Diagnostic Criteria for Multiple Sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-27.
12. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
13. Rio J, Nos C, Tintore M, Borras C, Galan I, Comabella M et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002; 52: 400-406.
14. Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, Pozzilli C et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003; 215: 3-8.
15. Kawade Y. Quantitation of neutralisation of interferon by antibody. Methods Enzymol 1986; 119: 558-73.
16. Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 126-38.
17. Sakamoto Y, Ishiguro M., Kitagawa G. Akaike information criterion statistics. KTK Scientific Publications, 1986.
18. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-82.
19. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W et al. The natural history of multiple sclerosis: a geographically based study. VII. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999; 122: 1941-50.
20. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R et al. Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-52.
21. Dubois BD, Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003; 74: 946-49.
22. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-32.
23. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
24. Confavreux C, Vukusic S, Moreau T, Adeline P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-38.
25. Thygesen P. The course or multiple sclerosis. Rosenkilde & Baggen, 1953.
26. Pittock SJ, McClelland RL, Mayr WT, Jorgensen NW, Weinshenker BG, Noseworthy J et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004; 56: 303-306.